Get the Stockscreener App
12.71
0.94%
-0.12
After Hours:
12.71
Adaptive Biotechnologies Corp stock is traded at $12.71, with a volume of 1.59M.
It is down -0.94% in the last 24 hours and down -12.16% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$12.83
Open:
$12.82
24h Volume:
1.59M
Relative Volume:
0.85
Market Cap:
$2.03B
Revenue:
$276.98M
Net Income/Loss:
$-59.46M
P/E Ratio:
-31.88
EPS:
-0.3987
Net Cash Flow:
$-48.95M
1W Performance:
-6.13%
1M Performance:
-12.16%
6M Performance:
-7.56%
1Y Performance:
+40.44%
1-Day Range:
$12.50
$13.39
1-Week Range:
$12.50
$13.72
52-Week Range:
$8.50
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
12.71 | 2.05B | 276.98M | -59.46M | -48.95M | -0.3987 |
TMO
Thermo Fisher Scientific Inc
|
442.00 | 162.90B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
163.86 | 114.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
545.79 | 41.71B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
332.19 | 32.32B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.11 | 31.57B | 7.07B | 1.29B | 993.00M | 4.5355 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Proposed sale of 3,160 RSUs by ADPT (NASDAQ: ADPT) reported - Stock Titan
Viking firms hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT) - Stock Titan
ADPT Stock Price, Quote & Chart | ADAPTIVE BIOTECHNOLOGIES (NASDAQ:ADPT) - ChartMill
ADPT SEC FilingsAdaptive Biotechnologies 10-K, 10-Q, 8-K Forms - Stock Titan
ADPT Maintained by Morgan Stanley -- Price Target Lowered to $18 - GuruFocus
Morgan Stanley Cuts Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $18.00 - MarketBeat
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance - Yahoo Finance
Analysts Expect Breakeven For Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Before Long - Moomoo
How Strong MRD Growth and Upgraded 2026 Guidance Will Impact Adaptive Biotechnologies (ADPT) Investors - simplywall.st
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript - Insider Monkey
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised - Investing.com Australia
Adaptive Biotechnologies (NASDAQ:ADPT) Given Buy Rating at Guggenheim - MarketBeat
Adaptive Biotechnologies Corporation 10-Q Report 2026: Financial Statements, Risk Factors, and Forward-Looking Statements 173031 - Minichart
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised By Investing.com - Investing.com South Africa
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast - Investing.com
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call - Benzinga
Adaptive Biotechnologies: Q1 Earnings Snapshot - marketscreener.com
Adaptive Biotechnologies Corp reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Adaptive Biotechnologies Corp Quarterly Earnings Report - Stock Titan
Q1 2026 Adaptive Biotechnologies Corp Earnings Call Transcript - GuruFocus
MSN Money - MSN
Adaptive Biotechnologies (NASDAQ: ADPT) lifts 2026 MRD outlook after 35% Q1 revenue growth - Stock Titan
Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain - Stock Titan
Adaptive Biotechnologies earnings on deck after 55% revenue surge By Investing.com - Investing.com South Africa
Adaptive Biotechnologies earnings on deck after 55% revenue surge - Investing.com
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - Yahoo Finance
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares - Investing.com
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions - Yahoo Finance
Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock By Investing.com - Investing.com UK
Adaptive Biotechnologies Corp (HAM:1HM) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Adaptive Biotechnologies Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Valuation: Significantly Overvalued - GuruFocus
Adaptive Biotechnologies Corp Stock Intrinsic Values | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Historical Valuations | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Operating Data - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Adaptive Biotechnologies Corp Stock Baskets | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):